Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 2.95
(-1.5%)
SEK 2.95
(-1.5%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -23.76 SEK | 85.98% |
| 2022 | -169.43 SEK | 23.4% |
| 2021 | -221.20 SEK | 15.69% |
| 2020 | -262.38 SEK | -4.8% |
| 2019 | -250.37 SEK | -20.77% |
| 2018 | -207.31 SEK | -37.59% |
| 2017 | -150.67 SEK | 35.53% |
| 2016 | -233.71 SEK | -42.85% |
| 2015 | -163.61 SEK | 21.83% |
| 2014 | -209.31 SEK | 2.19% |
| 2013 | -214.00 SEK | -28818.92% |
| 2012 | -0.74 SEK | -428.57% |
| 2011 | -0.14 SEK | -27.27% |
| 2010 | -0.11 SEK | -158.22% |
| 2009 | -0.04 SEK | -86.03% |
| 2008 | -0.02 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.98 SEK | 42.35% |
| 2024 Q1 | -1.70 SEK | 55.03% |
| 2024 Q3 | -0.98 SEK | 0.0% |
| 2023 Q1 | -30.00 SEK | -111.86% |
| 2023 Q4 | -3.78 SEK | -15.95% |
| 2023 Q2 | -20.21 SEK | 32.63% |
| 2023 FY | - SEK | 85.98% |
| 2023 Q3 | -3.26 SEK | 83.87% |
| 2022 Q4 | -14.16 SEK | 83.14% |
| 2022 Q1 | -42.00 SEK | 28.73% |
| 2022 Q2 | -50.00 SEK | -19.05% |
| 2022 FY | - SEK | 23.4% |
| 2022 Q3 | -84.00 SEK | -68.0% |
| 2021 Q1 | -42.00 SEK | 37.62% |
| 2021 Q3 | -36.00 SEK | 59.09% |
| 2021 Q4 | -58.93 SEK | -63.69% |
| 2021 FY | - SEK | 15.69% |
| 2021 Q2 | -88.00 SEK | -109.52% |
| 2020 Q4 | -67.33 SEK | -60.31% |
| 2020 Q2 | -56.00 SEK | 45.1% |
| 2020 FY | - SEK | -4.8% |
| 2020 Q1 | -102.00 SEK | -17.71% |
| 2020 Q3 | -42.00 SEK | 25.0% |
| 2019 Q4 | -86.65 SEK | -80.52% |
| 2019 FY | - SEK | -20.77% |
| 2019 Q3 | -48.00 SEK | 20.0% |
| 2019 Q1 | -54.00 SEK | 1.5% |
| 2019 Q2 | -60.00 SEK | -11.11% |
| 2018 FY | - SEK | -37.59% |
| 2018 Q1 | -6.76 SEK | 77.94% |
| 2018 Q4 | -54.82 SEK | -30.52% |
| 2018 Q3 | -42.00 SEK | 53.33% |
| 2018 Q2 | -90.00 SEK | -1231.36% |
| 2017 FY | - SEK | 35.53% |
| 2017 Q4 | -30.65 SEK | -9.46% |
| 2017 Q3 | -28.00 SEK | 13.39% |
| 2017 Q2 | -32.33 SEK | 43.15% |
| 2017 Q1 | -56.87 SEK | -41.5% |
| 2016 FY | - SEK | -42.85% |
| 2016 Q2 | -52.34 SEK | 24.61% |
| 2016 Q1 | -69.43 SEK | -54.63% |
| 2016 Q3 | -65.94 SEK | -25.98% |
| 2016 Q4 | -40.19 SEK | 39.05% |
| 2015 Q3 | -37.14 SEK | 0.56% |
| 2015 Q4 | -44.90 SEK | -20.89% |
| 2015 FY | - SEK | 21.83% |
| 2015 Q2 | -37.35 SEK | 18.2% |
| 2015 Q1 | -45.66 SEK | 55.08% |
| 2014 FY | - SEK | 2.19% |
| 2014 Q4 | -101.65 SEK | -179.03% |
| 2014 Q2 | -40.81 SEK | -34.2% |
| 2014 Q3 | -36.43 SEK | 10.73% |
| 2014 Q1 | -30.41 SEK | 59.08% |
| 2013 Q4 | -74.31 SEK | -61.54% |
| 2013 Q2 | -52.00 SEK | -23.81% |
| 2013 Q3 | -46.00 SEK | 11.54% |
| 2013 FY | - SEK | -28818.92% |
| 2013 Q1 | -42.00 SEK | -16053.85% |
| 2012 Q4 | -0.26 SEK | -23.81% |
| 2012 Q2 | -0.04 SEK | 28.66% |
| 2012 Q1 | -0.05 SEK | 72.67% |
| 2012 FY | - SEK | -428.57% |
| 2012 Q3 | -0.21 SEK | -498.29% |
| 2011 Q3 | -0.02 SEK | 25.69% |
| 2011 Q2 | -0.03 SEK | 4.53% |
| 2011 Q1 | -0.03 SEK | 71.23% |
| 2011 Q4 | -0.18 SEK | -857.45% |
| 2011 FY | - SEK | -27.27% |
| 2010 Q2 | -0.02 SEK | 52.94% |
| 2010 FY | - SEK | -158.22% |
| 2010 Q3 | -0.02 SEK | -23.81% |
| 2010 Q1 | -0.04 SEK | 16.59% |
| 2010 Q4 | -0.09 SEK | -342.79% |
| 2009 Q2 | -0.01 SEK | 72.03% |
| 2009 Q1 | -0.03 SEK | -291.98% |
| 2009 FY | - SEK | -86.03% |
| 2009 Q4 | -0.04 SEK | -403.53% |
| 2009 Q3 | -0.01 SEK | 2.3% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q4 | 0.02 SEK | 220.9% |
| 2008 Q3 | -0.01 SEK | 16.25% |
| 2008 Q2 | -0.02 SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Acarix AB (publ) | -0.16 SEK | -14750.0% |
| ADDvise Group AB (publ) | 0.56 SEK | 4342.857% |
| ADDvise Group AB (publ) | 0.56 SEK | 4342.857% |
| Arcoma AB | 0.19 SEK | 12605.263% |
| Bactiguard Holding AB (publ) | -3.95 SEK | -501.519% |
| BICO Group AB (publ) | -12.99 SEK | -82.91% |
| Boule Diagnostics AB (publ) | 0.64 SEK | 3812.5% |
| CellaVision AB (publ) | 5.46 SEK | 535.165% |
| Chordate Medical Holding AB (publ) | -0.13 SEK | -18176.923% |
| C-Rad AB (publ) | 1.05 SEK | 2362.857% |
| Duearity AB (publ) | -0.40 SEK | -5840.0% |
| Dignitana AB (publ) | -0.25 SEK | -9404.0% |
| Episurf Medical AB (publ) | -0.36 SEK | -6500.0% |
| Getinge AB (publ) | 8.86 SEK | 368.172% |
| Scandinavian Real Heart AB (Publ) | -0.70 SEK | -3294.286% |
| Iconovo AB (publ) | -4.39 SEK | -441.23% |
| Integrum AB (publ) | 0.23 SEK | 10430.435% |
| Luxbright AB (publ) | -0.37 SEK | -6321.622% |
| Mentice AB (publ) | -0.11 SEK | -21500.0% |
| OssDsign AB (publ) | -1.59 SEK | -1394.34% |
| Paxman AB (publ) | 0.44 SEK | 5500.0% |
| Promimic AB (publ) | -0.50 SEK | -4652.0% |
| Qlife Holding AB (publ) | -526.52 SEK | 95.487% |
| SciBase Holding AB (publ) | -0.51 SEK | -4558.824% |
| ScandiDos AB (publ) | -0.32 SEK | -7325.0% |
| Sectra AB (publ) | 2.22 SEK | 1170.27% |
| Sedana Medical AB (publ) | -0.60 SEK | -3860.0% |
| Senzime AB (publ) | -1.45 SEK | -1538.621% |
| SpectraCure AB (publ) | -0.21 SEK | -11214.286% |
| Stille AB | 5.31 SEK | 547.458% |
| Vitrolife AB (publ) | -28.44 SEK | 16.456% |
| Xvivo Perfusion AB (publ) | 3.07 SEK | 873.941% |